Symbiosis C.M.
Personalized Transcatheter Heart Valve Replacement
Company Overview
Snapshot
Founded in February 2021 by Shira Burg, Symbiosis C.M. operates with 11–50 employees. The company has completed 5 funding rounds. In December 2024, Symbiosis C.M. welcomed Prof. Marc Gillinov to its Advisory Board, enhancing its strategic guidance in the medical device sector.
Business overview
Symbiosis C.M. is a medical device company focused on addressing anatomical variability in valvular heart disease. The company develops solutions to improve the fit and performance of existing medical devices, as well as standalone products for anatomies with significant inter-patient variability. Its primary product, ValSync, is a minimally invasive personalized solution for valve replacement, serving the healthcare and medical devices industries within the Health Tech & Life Sciences sector.
Strategic signal
In December 2024, Symbiosis C.M. won the TCT 2024 Shark Tank Innovation Competition. This achievement signals strong validation of the company's innovative approach to personalized transcatheter heart valve replacement and highlights its potential for disruption in the cardiology and medical device markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Symbiosis C.M.'s core product?
- Symbiosis C.M.'s first product is ValSync, a minimally invasive personalized solution designed for valve replacement, addressing anatomical variability in valvular heart disease.
- When was Symbiosis C.M. founded?
- Symbiosis C.M. was founded in February 2021.
- What recognition did Symbiosis C.M. receive in late 2024?
- In December 2024, Symbiosis C.M. won the TCT 2024 Shark Tank Innovation Competition.
- Who is the founder of Symbiosis C.M.?
- Shira Burg is the Founder & CEO of Symbiosis C.M.
- What significant addition was made to Symbiosis C.M.'s Advisory Board?
- In December 2024, Symbiosis C.M. welcomed Prof. Marc Gillinov to its Advisory Board.